Polyplus

31/08/2022

Webinar: Next generation lipid-based delivery for mRNA therapeutics: in vivo-jetRNA®+

Join us and hear from Polyplus expert panel Dr. Malik Hellal and Dr. Claire Gueguen present Polyplus’ latest innovation for mRNA therapeutics. In vivo-jetRNA®+ is a ready to use lipid-based transfection reagent specifically developed to address current limit of LNPs in targeting different organs and cell types

In this webinar, you'll be given a tour of the numerous perks in vivo-jetRNA®+ has to offer.

When: September 6th 2022 at 5pm CET & September 7th at 9:30pm CET.
Where: Live webinar
Who: Claire Guéguen, PhD, Head of R&D Life Science at Polyplus & Malik Hellal, PhD, Senior Scientist in Chemistry at Polyplus.

Register now!

23/08/2022

[A Right-First-Time Approach to Viral Vector Manufacturing]

Accounting for quality and scalability into viral-vector manufacturing processes from the outset is not only more efficient, but also essential to enabling the cost-effective production of large quantities of gene therapies.

In our article (and webinar), we discussed the ways in which two fundamental actions are being taken at Polyplus and Exothera Inside : process optimization and scaling. Learn about approaches to overcoming current issues limiting the available capacity for viral-vector manufacturing and thus making gene therapies accessible to more patients.

An overview to Viral Vector Manufacturing: Designing Quality and Scalability into Transient Transfection Processes from the Outset. A Right-First-Time Approach in a webinar.

16/08/2022

If you missed our "Production of difficult-to-express proteins: strategies to increase the success rate" it's now available in replay!

Proteins are of pivotal interest for research, development and pharmaceutical applications. Nowadays, they are usually produced recombinantly in different prokaryotic or eukaryotic expression systems. Many proteins of interest are difficult to express and consequently final yields and activities prove unacceptable and production processes need laborious optimization.

We present different strategies to increase the initial success rate for production of difficult-to-express target proteins with Rheinhold Horlascher, Managing DFirector/CSO at Trenzyme-GmbH.

Learn about different strategies to increase the initial success rate for production of difficult-to-express target proteins.

14/07/2022

webinar Production of difficult-to-express proteins: strategies to increase the success rate

Proteins are of pivotal interest for research, development and pharmaceutical applications. Nowadays, they are usually produced recombinantly in different prokaryotic or eukaryotic expression systems. Many proteins of interest are difficult to express and consequently final yields and activities prove unacceptable and production processes need laborious optimization.

We present different strategies to increase the initial success rate for production of difficult-to-express target proteins.

When: July 21th 2022 at 4pm CET
Where: Live webinar
Who: Reinhold Horlacher, PH.D., Managing Director/CSO at Trenzyme

Register now! ⬇️

Register now!

29/06/2022

Polyplus FectoVIR®-AAV GMP Enables Large Scale AAV Transient Transfection: learn more in this new The Cell Culture Dish article!

https://bit.ly/3QYkuYP

20/06/2022

Being at Polyplus headquarters gives a fantastic office experience: organic fruits are delivered weekly by B'on Fruits . 😋🍓🍑🍒🍌🍊🍐🍎🍏

Perfect for a healthy snack with colleagues!

17/06/2022

New : Cationic lipids offer new possibilities in liposome and LNP engineering for RNA therapeutics.

Ionizable lipid nanoparticles (LNPs) have been widely used for in vivo delivery of RNA therapeutics with the particular that they predominantly end up targeting the liver (Patisiran, BNTech162b, mRNA-1273). The current challenge is the use of commercially available lipids to have a better control over the biodistribution of the RNA once delivered systemically to target different organs and cell types.

Novel lipidic formulations using different cationic lipids were characterized and tested for mRNA delivery both in vitro and in vivo though intra-veinous and intramuscular injections to evaluate their stability, efficacy and biodistribution.

Our novel proprietary cationic lipid solves a current limit of LNPs to target different organs and cell types. Our novel lipidic formulations ensure the same efficacy as LNPs with ionizable lipids, while ensuring better biodistribution to target organs other than liver.

In this webinar we will present:
- How to maintain same delivery efficacy cationic lipid vs. ionizable lipid for LNP formulation
- How to achieve better biodistribution of LNPs by replacing ionizable lipid with cationic lipid.

When: Wednesday, June 29 | 2:30pm GMT+1 | 3:30pm CEST
Where: Live webinar
Who: Claire Guéguen, PhD, Head of R&D Life Science at Polyplus®.

https://bit.ly/3mUiUcw

15/06/2022

Improving Gene Therapy Viral Vector Manufacturing Economics: Modelling Bioprocess Costs​

Gene therapy viral vector manufacturers strive to reduce time to market and cost per dose to ensure treatment affordability and patient access. Approved and commercialized AAV-based gene therapies Luxturna® and Zolgensma®, for patients suffering from vision loss and spinal muscular atrophy, are the first of many gene therapies that are expected to reach the market in the coming years. One major bottleneck is the cost per dose of the treatments, with Luxturna® costing almost half a million dollars per eye and Zolgensma® reaching two million dollars.

In this Ask the expert webinar with and Corporation, topics covered are:
➡What have we learned from marketed gene therapies?
➡How can we rely on cost-modelling to reduce manufacturing cost of viral vectors?
➡What innovative tools in the gene therapy space can bring the cost of viral vector manufacturing down?

When: June 23th 2022 at 11 am EDT | 8 am PDT | 5 pm CET
Where: Live webinar
Who: Emmanuelle Cameau, Strategic Technology Partnership Leader, Cell and Gene Therapy,Pall Corporation & Maxime Dumont, Cell & Gene Therapy Product Manager, Polyplus.



https://bit.ly/3Qlwtz9

14/06/2022

[Botechnology]

Everything you always wanted to know about current GMP compliance (but were afraid to ask) : our Regulatory Affairs Specialist at Polyplus® gives us clear answers!

https://bit.ly/39lTWQ5

Since many AMs are complex biological materials, evaluating their qualities can be challenging. The intricacy of biologics, as well as the application of